Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

ConclusionsLenvatinib 12-mg QD showed clinical activity and acceptable toxicity profiles in patients with advanced HCC, but early dose modification was necessary in patients with lower body weight. Further development of lenvatinib in HCC should consider dose modification by body weight.Trial registration IDwww.ClinicalTrials.gov NCT00946153.

http://link.springer.com/10.1007/s00535-016-1263-4

Source: Journal of Gastroenterology - October 3, 2016 Category: Gastroenterology Source Type: research